Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2014. For the quarter, revenue from continuing operations was $327.6 million, an increase of 12.1% from $292.1 million in the third quarter of 2013. Revenue growth was driven by the acquisition of Argenta and BioFocus, which was completed on April 1, 2014 and contributed 8.0% to third-quarter revenue, as well as double-digit growth in the Manufacturing Support segment. Foreign currency translation benefited reported revenue by 0.4%.
Help employers find you! Check out all the jobs and post your resume.
